ServoSoft LLC

Consulting

Senior, hands-on, accountable to the work.

ServoSoft engagements are built around the kind of problems that don't survive being handed off to junior staff: ambiguous scope, regulated environments, and decisions that compound over years.


01 — Architecture & Strategy

Cloud Architecture for Regulated R&D

AWS reference architectures for clinical and pharmacometrics workloads. Identity, networking, storage, and compute decisions documented so they hold up under audit. GxP validation strategy, 21 CFR Part 11 alignment, and retrospective validation when the paperwork didn't keep up with the build.

02 — Clinical Systems

EDC, eTMF, CTMS Integration

Vendor selection, integration architecture, and the operational seams between systems and CROs. Particular interest in organizations untangling legacy footprints or moving from a single vendor stack to best-of-breed.

03 — AI & Agents

AI Agent Platforms

Production patterns for multi-agent systems on AWS — orchestration, inter-agent messaging, evaluation, and the governance work that makes the output usable for clinical and regulatory document workflows. Bedrock AgentCore and Strands evaluation, local-LLM strategies for sensitive document analysis.

04 — Advisory

IT Business Partner Engagements

Fractional or interim IT business partner work for R&D functions — clinical, biostatistics, pharmacometrics, regulatory. For organizations that need a senior counterpart to the science but don't yet need the role full-time.


How it works

Most engagements start with a scoped two-to-four week assessment. Output is a written deliverable — architecture, recommendation, plan — that stands on its own whether or not the implementation work continues with me.

Implementation engagements are typically retainer-based with a defined deliverable and review cadence. I work primarily remote, with occasional on-site time for stakeholder workshops or audit support.

ServoSoft LLC is a Florida-domiciled entity. Engagements are governed by a standard MSA + SOW structure and can accommodate the contracting requirements of public biopharma sponsors.

Start a conversation →